Response-driven movement control with AUSTEDO1

Multiple therapeutic dosing options starting at 24 mg/day

Dial representing multiple dosing options that can range from 24mg/day to 48mg/day. Dial representing multiple dosing options that can range from 24mg/day to 48mg/day. Dial representing multiple dosing options that can range from 24mg/day to 48mg/day.

In clinical trials, the average daily dose of AUSTEDO was >36 mg/day2,3

  • In the ARM-TD study, the mean total daily dose was 38.3 mg1
  • In the open-label extension study, the average required dose of AUSTEDO was
    >38 mg/day2

AUSTEDO offers dosing options to help patients effectively and tolerably reach symptom control1

Please see additional dosing and administration information at the bottom of this page.

AUSTEDO dosing should increase until symptom control is tolerably achieved 1

Start treatment at 12 mg/day

Blue arrow pointing right Blue arrow pointing right

Increase by 6 mg/day weekly until desired symptom control is reached

Ascending bar graph to represent the titration schedule through Week 7. Ascending bar graph to represent the titration schedule through Week 7.

AUSTEDO is available in 6-mg, 9-mg, and 12-mg tablets1

6 mg AUSTEDO®  (deutetrabenazine) tablet.9 mg AUSTEDO®  (deutetrabenazine) tablet. 12 mg AUSTEDO®  (deutetrabenazine) tablet.

Tablets not shown at actual size.

Purple glass icon.

Additional dosing and administration information1

  • Administer total daily dosages in 2 divided doses
  • The maximum recommended daily dosage of AUSTEDO is 48 mg (24 mg twice daily)
  • AUSTEDO should be taken with food
  • AUSTEDO should be swallowed whole. Tablets should not be chewed, crushed, or broken
Purple video icon.

Watch TD Movements Over Time

See Charlene’s treatment journey—find information on titration and the effects on symptom control.

See Charlene’s treatment journey—find information on titration and the effects on symptom control.

REFERENCES: 1. AUSTEDO® (deutetrabenazine) tablets current Prescribing Information. Parsippany, NJ, Teva Neuroscience, Inc. 2. Fernandez HH, Stamler D, Davis MD, et al. Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. J Neurol Neurosurg Psychiatry. 2019;90(12):1317-1323. doi:10.1136/jnnp-2018-319918 3. Data on file. North Wales, PA: Teva Neuroscience, Inc.